neurology

News

Biogen's R&D strategy fails to impress after Alzheimer's tri...

The dust has settled at Biogen following the company’s disastrous announcement that it was ending development of Alzheimer’s drug aducanumab, and in its latest Q1 figures the company hoped

News

Illustration of a nerve cell on a colored background with light effects

Alder gears up for migraine showdown with eptinezumab filing

Alder BioPharmaceuticals has filed its migraine drug eptinezumab with the US regulator, the last in a gang of four CGRP-class antibodies developed to treat the condition.

News

European regulator restricts use of Sanofi MS drug Lemtrada

The European drug regulator has called for a review of Sanofi’s multiple sclerosis drug Lemtrada following reports of immune-related conditions and sometimes fatal problems with the heart a

News

Novartis sues as Amgen tries to cancel migraine tie-up

Novartis and Amgen have become embroiled in a legal row over rights to the migraine prevention drug Aimovig, as sales of a new class of injected drugs begin to mount.

News

Teva's migraine drug Ajovy approved in Europe

Teva’s migraine drug Ajovy (fremanezumab) has been approved in Europe, taking on rivals from the same class from Novartis and Eli Lilly.

News

MS drug market heats up as FDA backs Novartis' new pill

The FDA has approved Novartis’ Mayzent (siponimod) multiple sclerosis pill for relapsing forms of the disease, dealing a potential blow to a much-delayed rival from Celgene.

Biogen's R&D strategy fails to impress after Alzheimer's tri...

Alder gears up for migraine showdown with eptinezumab filing

European regulator restricts use of Sanofi MS drug Lemtrada

Novartis sues as Amgen tries to cancel migraine tie-up

Teva's migraine drug Ajovy approved in Europe

MS drug market heats up as FDA backs Novartis' new pill

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

neurology

Editor's Picks